Wowwwwww. The American Cancer Society finally came out with the new colorectal cancer screening guidelines, and stool-DNA has been approved! This is huge for EXAS.
2 million shares traded so far just 3 hours into the day.... Conference Call scheduled after the close regarding the recent ACS Guideline inclusion and current 510k negotiations with the FDA. EXAS: $3.42 $+1.33 ( High of $4.25 off the opening )
In tomorrow's NY Times . . . Already on the "online" version: http://www.nytimes.com/2008/03/06/health/research/06cancer.html
The Company announced today that they have hired healthcare investment banker LEERINK SWANN to explore "strategic" options . . . In other words, this company and its 37 patents on stool-DNA colorectal cancer screening is now in PLAY. Hello Roche? Abbott Labs? Genetech?